Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to March 2026, from the company's annual filing with the SEC.
| Salesyearly sales | $2.0B |
| Sales growthchange from the year before | +5.3% |
| Gross marginshare of sales left after the direct cost of what it sells | 52.8% |
| Operating marginshare of sales left after running the business | 23.0% |
| Net marginshare of sales kept as profit | 20.7% |
| Free-cash-flow marginspare cash generated per $100 of sales | 31.9% |
| Return on invested capitalprofit made on each $100 put into the business | 17.3% |
| Return on equityprofit vs. shareholders' accounting value | 19.7% |
| Interest coverhow many times profit covers interest payments | 512.7x |
| Change in share countnegative = the company is buying back its shares | -4.4% |
1 insider sold $162K (all under pre-arranged plans) on the open market.
| Baumgartner Jeffrey WEvp, R&D | Sold (plan)Jul 20 | 1,166 shat $138.57 · $162K |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy